Current Topics in iPSCs Technology

Current Topics in iPSCs Technology

1st Edition - January 18, 2022

Write a review

  • Editor: Alexander Birbrair
  • Paperback ISBN: 9780323998925
  • eBook ISBN: 9780323983983

Purchase options

Purchase options
DRM-free (PDF, EPub)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Current Topics in iPSCs provides a deep analysis of the underlying fundamentals that support short and mid-term developments and milestones in the business of mesenchymal stem cell therapies. This volume explores the next frontier of MSC therapies and how the transformational potential of therapeutic adult cells will be realised in all therapy areas. The impacts of clinical and economic benefits are dissected throughout each of the chapters. Written by thought leaders in the field for those curious about the interface of science and business.

Key Features

  • Explores the strategy at the forefront of the science of mesenchymal stem cells
  • Provides an overview of all therapy areas where MSC and MSC-derived products can be used therapeutically
  • Depicts transformational changes in healthcare that enable the implementation of MSC-powered technology platforms


Researchers and scientists in stem cell therapy, cell biology, regenerative medicine, and organ transplantation; Graduate and undergraduate students in the above fields

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Advances in Stem Cell Biology
  • Copyright
  • Dedication
  • Contributors
  • About the editor
  • Preface
  • Acknowledgment
  • Chapter 1. Regulatory and policy considerations in iPSC research
  • Introduction
  • Three primary domains
  • Materials acquisition
  • iPSC derivation and differentiation
  • Product and data stewardship
  • Conclusion
  • Chapter 2. hiPSCs for population genetics
  • Introduction
  • hiPSCs for disease-related genetics and functional genomics
  • hiPSC for pharmacogenomics
  • Future directions
  • Chapter 3. Using human induced pluripotent stem cells to advance personalized/precision medicine
  • Introduction
  • hiPSCs in patient-specific genome research
  • hiPSCs in patient-specific epigenome research
  • hiPSCs in patient-specific proteomic research
  • hiPSCs in patient-specific metabolomic research
  • Example of using hiPSCs to establish a databank for large-scale personalized medicine
  • Challenges of hiPSC disease modeling
  • Chapter 4. hiPSC disease modeling with 3D organoids: bioengineering perspective
  • Introduction
  • Organoid differentiation and characterization
  • Applications
  • Perspective
  • Conclusions
  • Chapter 5. The differentiation of embryonic stem cells and induced pluripotent stem cells into airway and alveolar epithelial cells
  • Introduction
  • Murine and human lung development
  • ESC and human IPSC differentiation into airway and alveolar epithelial cells
  • Conclusion
  • Chapter 6. Transplantation of human iPSC-derived kidney organoids
  • Introduction
  • Metanephric grafts
  • Limitations of kidney organoids
  • Implantation into neonatal mice
  • Formation of glomerulus-like structures
  • Readouts of glomerular function
  • Organoids as regenerative therapeutics
  • Safety concerns
  • Conclusion
  • Chapter 7. An update on clinical applications of iPSCs from a genomic point of view
  • Introduction
  • Types of genomic aberrations
  • Origin of genomic aberrations in iPSCs
  • Effects of mutations on the phenotype of iPSCs
  • Improved reprogramming methods to reduce genomic instability
  • Conclusions and future outlook
  • Chapter 8. Replication-associated DNA damage in induced pluripotent stem cells
  • Introduction
  • Genomic instability in PSCs
  • DNA damage, repair, and response in PSCs
  • Potential sources of replication-associated DNA damage in PSCs
  • DNA damage response in PSCs
  • Commentary: future trends and directions
  • Chapter 9. Epigenetic modifications in induced pluripotent stem cells to boost myogenic commitment
  • Epigenetics
  • Myogenesis
  • Differentiating iPSCs toward the skeletal muscle lineage
  • Epigenetic memory
  • Epigenetics in skeletal muscle differentiation
  • Epigenetic modifications to improve skeletal muscle differentiation
  • Future perspectives
  • Chapter 10. Applications for induced pluripotent stem cells in reproductive medicine
  • Introduction
  • Cellular and molecular mechanisms of human germ cell development—a roadmap for the derivation of germ cells from hiPSCs
  • Potential use of hiPSC-derived gametes—unmet needs in ARTs and research models
  • Generation of hiPSC-derived germ cells
  • Patient-specific modeling of gametogenesis using hPGCLCs
  • iPSC-derived reproductive somatic cells
  • Challenges and future directions
  • Chapter 11. iPSCs in insulin resistance, type 2 diabetes, and the metabolic syndrome
  • Introduction
  • Insulin resistance, type 2 diabetes, and the metabolic syndrome
  • iPSC differentiation to relevant metabolic cell types
  • iPSC-based models for insulin resistance, type 2 diabetes, and the metabolic syndrome
  • Future directions
  • Chapter 12. Induced pluripotent stem cells for cystic fibrosis
  • Introduction
  • Generalities of iPSCs
  • Cystic fibrosis
  • Functional assay for CFTR or assay for measuring CFTR activity (Fig. 12.1)
  • iPSCs for the respiratory system (Table 12.2)
  • iPSCs for the gatrointestinal system (Table 12.3)
  • Concluding remarks and future directions
  • Declaration of interest
  • Chapter 13. Exploring 15q13.3 copy number variants in iPSCs
  • Introduction
  • More work to be done
  • Chapter 14. Human induced pluripotent stem cells for modeling Brugada syndrome
  • Introduction
  • Long QT syndrome
  • Catecholaminergic polymorphic ventricular tachycardia
  • Brugada syndrome
  • Short QT syndrome
  • Human induced pluripotent stem cells
  • Human cardiomyocytes from induced pluripotent stem cells
  • Brugada syndrome animal models
  • Heterologous expression systems
  • Native human cardiomyocytes
  • Brugada syndrome models using hiPSC-CMs
  • Limitations of hiPSC-CMs
  • Chapter 15. iPSCs for erythromycin arrhythmogenicity testing
  • Introduction
  • The occurrence of ventricular fibrillation, prognostic difficulties
  • Experimental modeling approaches: iPSCs
  • Timeline for arrhythmogenicity testing with a standard obstacle
  • Developing cellular systems for in vitro studies of erythromycin arrhythmogenicity
  • Future trends
  • Chapter 16. Therapeutic potential of induced pluripotent stem cell–derived extracellular vesicles: Quo Vadis? Terra incognito
  • Introduction
  • Extracellular vesicle nomenclature and characterization
  • Extracellular vesicle biogenesis and cargo types
  • Extracellular vesicle isolation and visualization approaches
  • Bioengineering and targeting of extracellular vesicles
  • Therapeutic application of adult stem cell–derived extracellular vesicles
  • Therapeutic application of pluripotent stem cell–derived extracellular vesicles
  • The road ahead
  • Chapter 17. Proteomic approach for creation of the protein marker panels to control the quality of human induced pluripotent stem cells
  • Introduction
  • Materials and methods
  • Results
  • Discussion
  • Conclusions
  • Chapter 18. Application of induced pluripotent stem cells in tissue engineering
  • Introduction
  • Stem cells
  • Different ways of scaffolds fabrication
  • Electrospinning
  • 3D printing
  • Biomaterials
  • Natural biomaterials
  • Synthetic biomaterials
  • iPSC applications in tissue engineering
  • Conclusion and iPSCs perspective in tissue engineering
  • Chapter 19. Induced pluripotent stem cell–derived extracellular vesicles in regenerative medicine
  • Introduction
  • Classification and biogenesis of EVs
  • Therapeutic potential of exosomes in cardiovascular disease
  • Therapeutic potential of microvesicles in cardiovascular disease
  • Current clinical perspective: challenges and promises of extracellular vesicles
  • Conclusion
  • Chapter 20. iPSCs and toxicology: predictive tool for present and future
  • Introduction: iPSCs in human toxicology
  • iPSCs in species-specific toxicology
  • Conclusions and future perspectives
  • Chapter 21. Rejuvenation through iPSCs and reprogramming in vivo and in vitro
  • What is aging?
  • Is aging universal? Is aging reversible or irreversible?
  • Mammalian/vertebrate aging
  • Can aging in complex adult organisms relevant to humans such as vertebrates that have reached sexual maturity be rejuvenated?
  • Rejuvenation by iPSC induction in vivo: first attempts by complete reprogramming
  • Rejuvenation by iPSC induction in vivo: partial reprogramming is successful
  • Rejuvenation by iPSC induction: follow-ups
  • Partial OSKM induction: kinetics of resetting DNAm age
  • Partial reprogramming of iPSCs: the future
  • Index

Product details

  • No. of pages: 636
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: January 18, 2022
  • Imprint: Academic Press
  • Paperback ISBN: 9780323998925
  • eBook ISBN: 9780323983983

About the Editor

Alexander Birbrair

Dr. Alexander Birbrair received his bachelor’s biomedical degree from Santa Cruz State University in Brazil. He completed his PhD in Neuroscience, in the field of stem cell biology, at the Wake Forest School of Medicine under the mentorship of Osvaldo Delbono. Then, he joined as a postdoc in stem cell biology at Paul Frenette’s laboratory at Albert Einstein School of Medicine in New York. In 2016, he was appointed faculty at Federal University of Minas Gerais in Brazil, where he started his own lab. His laboratory is interested in understanding how the cellular components of different tissues function and control disease progression. His group explores the roles of specific cell populations in the tissue microenvironment by using state-of-the-art techniques. His research is funded by the Serrapilheira Institute, CNPq, CAPES, and FAPEMIG. In 2018, Alexander was elected affiliate member of the Brazilian Academy of Sciences (ABC), and, in 2019, he was elected member of the Global Young Academy (GYA), and in 2021, he was elected affiliate member of The World Academy of Sciences (TWAS). He is the Founding Editor and Editor-in-Chief of Current Tissue Microenvironment Reports, and Associate Editor of Molecular Biotechnology. Alexander also serves in the editorial board of several other international journals: Stem Cell Reviews and Reports, Stem Cell Research, Stem Cells and Development, and Histology and Histopathology.

Affiliations and Expertise

Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Department of Radiology, Columbia University Medical Center, Medical Center, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Current Topics in iPSCs Technology"